Issues with our digital services

We're investigating why they're not working as they should. Please bear with us.

BONES: The British Osteonecrosis Study.

  • Research type

    Research Study

  • Full title

    BONES: The British Osteonecrosis Study: A prospective multi-centre study to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma.

  • IRAS ID

    185365

  • Contact name

    Nadia L Amin

  • Contact email

    nadia.amin3@nhs.net

  • Sponsor organisation

    Unviersity of Leeds

  • Clinicaltrials.gov Identifier

    NCT02598401

  • Duration of Study in the UK

    5 years, 5 months, 31 days

  • Research summary

    As treatment for leukaemia has improved, we now expect to cure most children, teenagers and young adults who present with acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LL). Consequently there is an increased focus on improving quality of life during and after treatment without compromising cure. Osteonecrosis is one of the most debilitating complications, and is likely to occur as a consequence of the treatment given to patients. The patients at greatest risk of developing symptomatic osteonecrosis are the older children, teenage and young adult population, and this is the group the study focusses on. We aim to understand the incidence, risk factors and natural history of osteonecrosis in these patients with ALL and LL.

    This study will involve serial magnetic resonance imaging of lower limbs, markers of bone turnover and physiotherapy assessments of patients with ALL OR LL aged between 10 and 25 years. Investigations will occur within two weeks of diagnosis, at the end of delayed intensification and one, two and three years after the start of maintenance therapy. There will also be analysis of routine clinical imaging and investigations. The results should help us to identify early changes signifying potential development of symptomatic osteonecrosis, and lead to improved risk stratification of patients.

  • REC name

    Yorkshire & The Humber - Sheffield Research Ethics Committee

  • REC reference

    16/YH/0206

  • Date of REC Opinion

    12 Jul 2016

  • REC opinion

    Further Information Favourable Opinion